Gardasil

Treatment for Human Papillomavirus Prophylaxis

Merck Submits Biologics License Application to FDA for Gardasil, the Company's Investigational Vaccine for Cervical Cancer

Cervical cancer is the second most common cause of cancer death in women worldwide, resulting in a half-million diagnoses and approximately 300,000 deaths each year. In the United States an estimated 10,000 new cases of cervical cancer will be diagnosed in 2005. In most people, HPV goes away on its own. In some, however, certain high-risk types of HPV, if unrecognized and untreated, can lead to cervical cancer. Also, approximately one million cases of genital warts occur each year in the United States.

Source: Merck & Co., Inc.

Posted: December 2005

Related Articles

Gardasil (human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant) FDA Approval History

View comments

Hide
(web2)